| Literature DB >> 28624478 |
Wei Huang1, Liqing Chen1, Lin Kang1, Mingji Jin1, Ping Sun1, Xin Xin1, Zhonggao Gao2, You Han Bae3.
Abstract
Anticancer therapy has always been a vital challenge for the development of nanomedicine. Repeated single therapeutic agent may lead to undesirable and severe side effects, unbearable toxicity and multidrug resistance due to complex nature of tumor. Nanomedicine-based combination anticancer therapy can synergistically improve antitumor outcomes through multiple-target therapy, decreasing the dose of each therapeutic agent and reducing side effects. There are versatile combinational anticancer strategies such as chemotherapeutic combination, nucleic acid-based co-delivery, intrinsic sensitive and extrinsic stimulus combinational patterns. Based on these combination strategies, various nanocarriers and drug delivery systems were engineered to carry out the efficient co-delivery of combined therapeutic agents for combination anticancer therapy. This review focused on illustrating nanomedicine-based combination anticancer therapy between nucleic acids and small-molecular drugs for synergistically improving anticancer efficacy.Entities:
Keywords: Combination anticancer therapy; Drug delivery systems; Nanomedicine; Nucleic acids; Small-molecular drugs
Mesh：
Substances：
Year: 2017 PMID： 28624478 DOI： 10.1016/j.addr.2017.06.004
Source DB: PubMed Journal: Adv Drug Deliv Rev ISSN： 0169-409X Impact factor: 15.470